1. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. Issue 1 (27th February 2019) Authors: Cortellini, Alessio; Bersanelli, Melissa; Buti, Sebastiano; Cannita, Katia; Santini, Daniele; Perrone, Fabiana; Giusti, Raffaele; Tiseo, Marcello; Michiara, Maria; Di Marino, Pietro; Tinari, Nicola; De Tursi, Michele; Zoratto, Federica; Veltri, Enzo; Marconcini, Riccardo; Malorgio, Francesco; Rus... Journal: Journal for immunotherapy of cancer Issue: Volume 7:Issue 1(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. (March 2020) Authors: Cortellini, Alessio; Bersanelli, Melissa; Santini, Daniele; Buti, Sebastiano; Tiseo, Marcello; Cannita, Katia; Perrone, Fabiana; Giusti, Raffaele; De Tursi, Michele; Zoratto, Federica; Marconcini, Riccardo; Russano, Marco; Zeppola, Tea; Anesi, Cecilia; Filetti, Marco; Marchetti, Paolo; Botticelli... Journal: European journal of cancer Issue: Volume 128(2020) Page Start: 17 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: Case report and literature review. Issue 3 (January 2018) Authors: Falcone, Rosa; Roberto, Michela; Filetti, Marco; Anselmi, Elisabetta; Marchetti, Paolo Other Names: NA. section editor. Journal: Medicine Issue: Volume 97:Issue 3(2018) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Baseline BMI and BMI variation during first line pembrolizumab in NSCLC patients with a PD-L1 expression ≥ 50%: a multicenter study with external validation. Issue 2 (19th October 2020) Authors: Cortellini, Alessio; Ricciuti, Biagio; Tiseo, Marcello; Bria, Emilio; Banna, Giuseppe L; Aerts, Joachim GJV; Barbieri, Fausto; Giusti, Raffaele; Cortinovis, Diego L; Migliorino, Maria R; Catino, Annamaria; Passiglia, Francesco; Torniai, Mariangela; Morabito, Alessandro; Genova, Carlo; Mazzoni, Fr... Journal: Journal for immunotherapy of cancer Issue: Volume 8:Issue 2(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗